CN107007602A - 治疗阻塞性睡眠呼吸暂停的方法 - Google Patents
治疗阻塞性睡眠呼吸暂停的方法 Download PDFInfo
- Publication number
- CN107007602A CN107007602A CN201610821591.8A CN201610821591A CN107007602A CN 107007602 A CN107007602 A CN 107007602A CN 201610821591 A CN201610821591 A CN 201610821591A CN 107007602 A CN107007602 A CN 107007602A
- Authority
- CN
- China
- Prior art keywords
- sleep
- main body
- osa
- pharmaceutical composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 57
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229960002290 pyridostigmine Drugs 0.000 claims abstract description 76
- 230000007958 sleep Effects 0.000 claims abstract description 62
- 239000003814 drug Substances 0.000 claims abstract description 50
- 206010041235 Snoring Diseases 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 206010021079 Hypopnoea Diseases 0.000 claims description 37
- 239000008280 blood Substances 0.000 claims description 33
- 210000004369 blood Anatomy 0.000 claims description 33
- 208000008784 apnea Diseases 0.000 claims description 30
- 206010021143 Hypoxia Diseases 0.000 claims description 16
- 208000018875 hypoxemia Diseases 0.000 claims description 16
- 230000003860 sleep quality Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 15
- 230000002411 adverse Effects 0.000 abstract description 13
- 230000029058 respiratory gaseous exchange Effects 0.000 description 17
- 206010041349 Somnolence Diseases 0.000 description 16
- 239000003085 diluting agent Substances 0.000 description 11
- 230000031709 bromination Effects 0.000 description 10
- 238000005893 bromination reaction Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000002815 pulmonary hypertension Diseases 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- 208000037905 systemic hypertension Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- -1 acetylcholine ester Chemical class 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000024760 breath-holding Spells Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical class Br* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
- A61F5/56—Devices for preventing snoring
- A61F5/566—Intra-oral devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Nursing (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437272P | 2011-01-28 | 2011-01-28 | |
| US61/437,272 | 2011-01-28 | ||
| CN2012800065522A CN103458899A (zh) | 2011-01-28 | 2012-01-27 | 治疗阻塞性睡眠呼吸暂停的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012800065522A Division CN103458899A (zh) | 2011-01-28 | 2012-01-27 | 治疗阻塞性睡眠呼吸暂停的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107007602A true CN107007602A (zh) | 2017-08-04 |
Family
ID=46577943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610821591.8A Pending CN107007602A (zh) | 2011-01-28 | 2012-01-27 | 治疗阻塞性睡眠呼吸暂停的方法 |
| CN2012800065522A Pending CN103458899A (zh) | 2011-01-28 | 2012-01-27 | 治疗阻塞性睡眠呼吸暂停的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012800065522A Pending CN103458899A (zh) | 2011-01-28 | 2012-01-27 | 治疗阻塞性睡眠呼吸暂停的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8753327B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2672972B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014503593A (cg-RX-API-DMAC7.html) |
| CN (2) | CN107007602A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2825309C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012103398A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107007602A (zh) * | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| ES2721976T3 (es) * | 2014-03-03 | 2019-08-06 | Sleep Innovations Pty Ltd | Dispositivo para el tratamiento de la apnea del sueño |
| WO2016014229A1 (en) * | 2014-07-25 | 2016-01-28 | Mendelowitz David | Oxytocin improves treatment of obstructive sleep apnea |
| EP4186548A1 (en) | 2015-04-02 | 2023-05-31 | Hill-Rom Services PTE. LTD. | Mask leakage detection for a respiratory device |
| EP3558178B1 (en) * | 2016-12-23 | 2021-03-17 | Koninklijke Philips N.V. | System for treating snoring among at least two users |
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| DK3609472T3 (da) * | 2018-06-18 | 2021-04-06 | Kashiv Specialty Pharmaceuticals Llc | Forlænget frigivelsessammensætning indeholdende pyridostigmin |
| CN112601568B (zh) * | 2018-08-24 | 2024-07-26 | 皇家飞利浦有限公司 | 利用压力治疗系统提供睡眠治疗 |
| ES3049086T3 (en) | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| US20200281522A1 (en) | 2019-03-06 | 2020-09-10 | Medtronic Xomed, LLC | System and method for improved obstructive sleep apnea diagnostic for implantable devices |
| CN114504643B (zh) * | 2021-12-24 | 2024-03-26 | 北京大学第一医院 | 抗IgE抗体在用于治疗OSAS中的应用 |
| WO2024143302A1 (ja) * | 2022-12-28 | 2024-07-04 | 西川株式会社 | 健康リスク判定システム、自律神経判定システム、生活改善システム、寝姿勢判定システム、寝姿勢判定プログラム、歯ぎしり検出システム、および歯ぎしり検出プログラム |
| CN117402958B (zh) * | 2023-10-26 | 2026-05-15 | 天津医科大学总医院 | Claudin3及家族相关分子对阻塞性睡眠呼吸暂停低通气综合征的诊断价值 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034117A (en) * | 1995-12-19 | 2000-03-07 | A & Science Invest Ab | Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2247662B (en) | 1990-08-31 | 1994-11-02 | Instance Ltd David J | Labels and manufacture thereof |
| WO2005016327A2 (en) * | 2003-08-13 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
| EP1928445A1 (en) * | 2005-09-16 | 2008-06-11 | Cereuscience AB | Method and means of preventing and treating sleep disordered breathing |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US7984714B2 (en) * | 2006-09-29 | 2011-07-26 | Nellcor Puritan Bennett Llc | Managing obstructive sleep apnea and/or snoring using local time released agents |
| CN107007602A (zh) * | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
-
2012
- 2012-01-27 CN CN201610821591.8A patent/CN107007602A/zh active Pending
- 2012-01-27 US US13/359,692 patent/US8753327B2/en active Active
- 2012-01-27 EP EP12739245.4A patent/EP2672972B1/en active Active
- 2012-01-27 CN CN2012800065522A patent/CN103458899A/zh active Pending
- 2012-01-27 CA CA2825309A patent/CA2825309C/en active Active
- 2012-01-27 WO PCT/US2012/022825 patent/WO2012103398A2/en not_active Ceased
- 2012-01-27 JP JP2013551354A patent/JP2014503593A/ja active Pending
-
2014
- 2014-05-05 US US14/269,326 patent/US9295670B2/en active Active
-
2017
- 2017-01-04 JP JP2017000145A patent/JP6342525B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034117A (en) * | 1995-12-19 | 2000-03-07 | A & Science Invest Ab | Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method |
Non-Patent Citations (1)
| Title |
|---|
| 许庚: "《耳鼻咽喉科疾病临床诊断与治疗方案》", 31 August 2010, 科学技术文献出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017095485A (ja) | 2017-06-01 |
| CA2825309C (en) | 2019-10-01 |
| US8753327B2 (en) | 2014-06-17 |
| WO2012103398A2 (en) | 2012-08-02 |
| US20120197235A1 (en) | 2012-08-02 |
| EP2672972A2 (en) | 2013-12-18 |
| US20140238412A1 (en) | 2014-08-28 |
| WO2012103398A9 (en) | 2012-09-27 |
| US9295670B2 (en) | 2016-03-29 |
| EP2672972A4 (en) | 2014-09-10 |
| CN103458899A (zh) | 2013-12-18 |
| JP6342525B2 (ja) | 2018-06-13 |
| JP2014503593A (ja) | 2014-02-13 |
| CA2825309A1 (en) | 2012-08-02 |
| EP2672972B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2825309C (en) | Pyridostigmine for the treatment of obstructive sleep apnea | |
| Tingting et al. | Non-surgical treatment of obstructive sleep apnea syndrome | |
| Dicpinigaitis | Experimentally induced cough | |
| Zaremba et al. | Continuous positive airway pressure mitigates opioid-induced worsening of sleep-disordered breathing early after bariatric surgery | |
| PT705099E (pt) | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central | |
| Guilleminault et al. | Obstructive sleep apnea syndrome | |
| Simmons | Neurology of sleep and sleep-related breathing disorders and their relationships to sleep bruxism | |
| Vretzakis et al. | Influence of an external pacemaker on bispectral index | |
| Batra et al. | Ketamine pretreatment with venous occlusion attenuates pain on injection with propofol | |
| HK1241728A1 (en) | Methods for treating obstructive sleep apnea | |
| Davidson et al. | Neuromuscular blockade: Nursing interventions and case studies from infancy to adulthood | |
| Dalsasso et al. | Low-dose ketamine with clonidine and midazolam for adult day care surgery | |
| Balkan et al. | The laryngeal mask airway (LMA™) in paediatric ophthalmic anaesthesia practice | |
| Gogoi | Dr. Juganta Jyoti Gogoi, Dr. Anshul Singla, Dr. Amrita Puri, Dr. Rakshita Kathia and Dr. Atika Tulsyan | |
| Robertson | Intravenous anaesthesia and analgesia | |
| Kun et al. | A pilot experience of the use of intramuscular ketamine for paediatric sedation in an Accident and Emergency department | |
| Song et al. | Comparative Study of Dexmedetomidine Administration Routes in Pediatric Patients Receiving Endoscopic Low-temperature Plasma Adenotonsillar Ablation | |
| KR20250000641A (ko) | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 | |
| Dobbin et al. | Obstructive sleep apnea: recognition and management considerations for the aged patient | |
| Casati et al. | A clinical comparison between bispectral index (BIS) and high frequency EEG signal detection (SNAP) | |
| Tutiven | Anaesthesia for paediatric ophthalmic surgery | |
| Jiang et al. | Risk factors for bradycardia and desaturation in infants undergoing ophthalmological surgeries: a retrospective cohort study | |
| Turcios | Beta2-Adrenergic Agents in Asthma | |
| Sleep | Sleep Stages | |
| Eberhardie | Assessment of obstructive sleep apnoea/hypopnoea syndrome and its role in preventing stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1241728 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170804 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1241728 Country of ref document: HK |